About
Inomagen develops a non-viral gene therapy aimed at treating atrial fibrillation by targeting the underlying disease mechanisms through a single-dose, minimally invasive procedure.
Explore inomagen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.